Abstract
Glioblastoma (GBM) is the most common type of central nervous system tumors, and its patients have an extremely low survival rate. One of the factors responsible for this is the inefficacy of available therapies, among which the drug Temozolomide (TMZ) stands out. This chemotherapy drug saw its use solidified after being adopted as a standard treatment protocol. Its cytotoxicity arises fr…